Issues & Trends

Fantagio Corp.’s Produced Drama ‘Manager Kim’ a Hit in Both Ratings and Buzz

No. 1 in Viewership for 2026 Miniseries

Kwon Oh Seok
2026-07-27 10:46:58
[Edaily Reporter Kwon Oh Seok ] Comprehensive entertainment company Fantagio Corp.(032800)announced on the 27th that the SEOULBROADCASTINGSYSTEM Friday-Saturday drama “Manager Kim,” which it produced, successfully concluded its run after ranking first in viewership ratings among miniseries in 2026.
(Photo courtesy of Fantagio Corp.)

The final episode of “Manager Kim,” which aired on the 25th, recorded a nationwide viewership rating of 23% and a Seoul metropolitan area rating of 23.4% according to Nielsen Korea, with the peak viewership soaring to 27.1%. The company explained that the series maintained the top spot in viewership ratings for 2026 miniseries throughout its run, proving both its commercial success and popularity.
Industry observers regard “Manager Kim” as a prime example of Fantagio Corp.’s content planning and production capabilities. Analysts note that by producing the drama based on a proven original IP, the company has strengthened its business structure centered on in-house production.
Namgung Gyeon, Chairman of Fantagio Corp., stated, “Through this production, we have once again proven our content planning and production capabilities as well as our IP competitiveness,” adding, “We will continue to meet viewers’ expectations with high-quality content.”
Fantagio Corp. plans to use this box-office success as a springboard to accelerate the expansion of its content business. The company also plans to step up its push into the global market through upcoming projects based on its own IP.

Economy

Corporation

IT·Science

Economy

"AI Broadcasts on Its Own"... A Creator Startup Founded by a Former TikTok Employee [VC Cradle]

A virtual creator that doesn’t require a human actor has emerged. There is no pre-written script, nor is there an operator manipulating it in real time. Artificial intelligence (AI) hosts the broadcas…
2026-08-08 11:01:04

Corporation

Mezzion Pharma Co., Ltd. Simultaneously Improves Cysts and Kidney Function in ADPKD… “Moving Directly to Phase 2b Clinical Trials in Korea and the U.S.”

“When you examine the kidneys of mice with polycystic kidney disease, you can see large cysts. However, after administering Udenafil, a reduction in the size of these cysts was visible even to the nak…
2026-08-08 08:16:01

IT·Science

SK BIOPHARMACEUTICALS Soars on Cenobamate Growth… The Era of 45% Generic Drug Prices Begins [Weekly Bio Roundup]

(Graphic: Generative AI) During the first week of August (August 3–7), SK BIOPHARMACEUTICALS posted its best-ever quarterly earnings, driven by the growth of its new epilepsy drug “cenobamate.” Ad…
2026-08-08 08:31:03